Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Small study suggests natural HCV clearance is caused by AR3-antibody response

Publish date:: July 19, 2019

Key clinical point: A strong B-cell response producing cross-genotype and neutralizing antibodies, especially targeting AR3, contributes to hepatitis C virus clearance and long-term immune protection.

Major finding: A high frequency of cross-genotype antibodies was associated with spontaneous clearance of one or multiple HCV infections (P = .03).

Study details: Analysis of the B-cell repertoire of 13 injecting-drug users from the Amsterdam Cohort Study, with follow-up of a median 17.5 years after primary infection.

Disclosures: This study was supported by the Virgo consortium, funded by the Dutch government. Sabrina Merat and several coauthors are employees of AIMM Therapeutics, as well as shareholders.

Citation:

Merat SJ et al. J Hepatol. 2019;71:14-24.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Infectious Diseases

Obesity, hypoxia predict severity in children with COVID-19,

Prophylactic HIV treatment in female STI patients is rare,

Combo DAA treatments may benefit patients with resistant HCV genotype 3,

Pronounced racial differences in HBsAg loss after stopping nucleos(t)ide,

Opt-out policy at a syringe service program increased HIV/HCV testing,